Benazepril

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (12:52, 10 January 2024) (edit) (undo)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
-
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Benazepril/Benazepril/1" align="right" caption="Benazepril, also known as Lotensin"/>
+
<StructureSection load='' size='340' side='right' caption='Benazepril, also known as Lotensin' scene='Benazepril/Benazepril/1'>
===Better Known as: Lotensin (Lotrel when combined with Amlodipine)===
===Better Known as: Lotensin (Lotrel when combined with Amlodipine)===
* Marketed By: Novartis International AG<br />
* Marketed By: Novartis International AG<br />
Line 6: Line 6:
* Date of FDA Approval (Patent Expiration): 1991 (2003)<br />
* Date of FDA Approval (Patent Expiration): 1991 (2003)<br />
* 2002 Sales (Lotrel 2005 Sales): $300 Million ($1.2 Billion)
* 2002 Sales (Lotrel 2005 Sales): $300 Million ($1.2 Billion)
-
* Why You Should Care: One of the earliest and best selling [[Angiotensin-Converting Enzyme]] Inhibitors of all time.
+
* Importance: One of the earliest and best selling [[Angiotensin-Converting Enzyme]] Inhibitors of all time.
-
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
+
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases.
 +
 
===Mechanism of Action===
===Mechanism of Action===
Angiotensin II has been implicated in cardiac, renal and vascular diseases. <ref>PMID:17083068</ref> Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since [[ACE|ACE-1]] is the primary producer of Angiotensin II and degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure.<ref>PMID:15236580</ref>
Angiotensin II has been implicated in cardiac, renal and vascular diseases. <ref>PMID:17083068</ref> Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since [[ACE|ACE-1]] is the primary producer of Angiotensin II and degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure.<ref>PMID:15236580</ref>
-
 
+
</StructureSection>
===Pharmacokinetics===
===Pharmacokinetics===
-
{| class="wikitable" border="1" width="50%" style="text-align:center"
+
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">
-
|-
+
<tr>
-
! colspan="8" align="center"| ACE-Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID: 7867683</ref><ref>DOI: 10.1111/j.1365-2710.2005.00646.x</ref><ref>PMID: 16075412</ref><ref>PMID:7527101</ref>
+
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-
|-
+
<div style="height:100%; width: 100%">
-
! Parameter
+
{{:ACE Inhibitor Pharmacokinetics}}
-
! [[Captopril]]
+
</div>
-
! [[Lisinopril]]
+
</td>
-
! [[Ramipril]]
+
</tr>
-
! [[Enalapril]]
+
</table>
-
! [[Benazepril]]
+
-
! [[Perindopril]]
+
-
! [[Trandolapril]]
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+
-
! .98
+
-
! 6.5
+
-
! .67
+
-
! 1.06
+
-
! .5
+
-
! .75
+
-
! .72
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+
-
! 1210
+
-
! 79
+
-
! 16.4
+
-
! 314
+
-
! 149
+
-
! 105
+
-
! 1.68
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+
-
! 72
+
-
! 25
+
-
! 28
+
-
! 60
+
-
! 97
+
-
! 24
+
-
! 10
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
+
-
! 97
+
-
! 0
+
-
! 73
+
-
! 20
+
-
! 97
+
-
! 20
+
-
! 80
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
-
! .56
+
-
! 10.1
+
-
! 1.93
+
-
! 1.6
+
-
! 10
+
-
! .9
+
-
! .68
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
-
! 1673
+
-
! 1016
+
-
! 21.9
+
-
! 450
+
-
! 140
+
-
! 182
+
-
! 1.86
+
-
|-
+
-
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
-
! 1.1
+
-
! 5.5
+
-
! 5.0
+
-
! 5.4
+
-
! 1.7
+
-
! 2.4
+
-
! 2.5
+
-
|-
+
-
! Dosage (mg)
+
-
! 10
+
-
! 20
+
-
! 5
+
-
! 20
+
-
! 10
+
-
! 4
+
-
! 2
+
-
|-
+
-
! Metabolism
+
-
! Hepatic (CYP2D6)
+
-
! None
+
-
! Hepatic
+
-
! Hepatic (CYP3A4)
+
-
! Hepatic
+
-
! Hepatic
+
-
! Hepatic (CYP2D6 & CYP2C9)
+
-
|}
+
==References==
==References==

Current revision

Benazepril, also known as Lotensin

Drag the structure with the mouse to rotate

Pharmacokinetics

ACE-Inhibitor Pharmacokinetics Comparison at Equivalent Dosages
Parameter Captopril Lisinopril Ramipril Enalapril Benazepril Perindopril Trandolapril
Tmax (hr) .98 6.5 .67 1.06 .5 .75 .72
Cmax (ng/ml) 1210 79 16.4 314 149 105 1.68
Bioavailability (%) 72 25 28 60 97 24 10
Protein Binding (%) 97 0 73 20 97 20 80
T1/2 (hr) .56 10.1 1.93 1.6 10 .9 .68
AUC (ng/ml/hr) 1673 1016 21.9 450 140 182 1.86
IC50 (nM) 1.1 5.5 5.0 5.4 1.7 2.4 2.5
Dosage (mg) 10 20 5 20 10 4 2
Metabolism Hepatic (CYP2D6) None Hepatic Hepatic (CYP3A4) Hepatic Hepatic Hepatic (CYP2D6 & CYP2C9)

For Pharmacokinetic Data References, See: References

References

  1. ↑ Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006 Mar;7(1):3-14. PMID:17083068
  2. ↑ Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. PMID:15236580 doi:10.1021/bi049480n


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Benazepril"
Personal tools